Observational studyBMC infectious diseases2025
Effectiveness of remdesivir for hospitalized COVID-19 patients depending on the severity of respiratory status: a multicenter retrospective study in Japan.
Observational study in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRemdesivir, an antiviral nucleotide analog prodrug, is approved for clinical use against COVID-19 worldwide. However, its effectiveness varies depending on the respiratory failure status of patients. This study aimed to evaluate the effectiveness of remdesivir treatment based on the severity of respiratory failure, as indicated by the oxygen demand upon hospital admission. Subgroups analyses were conducted to identify patient groups that might benefit from remdesivir treatment.
methodsThis retrospective observational study (the J-RECOVER) enrolled patients with COVID-19 from 64 institutions in Japan between January 1 and September 30, 2020. Patients aged ≥ 18 years who were administered remdesivir within 3 days of hospital admission were included. A total of 3,591 patients were included, and propensity score overlap weighting analysis was used to compare in-hospital mortality based on respiratory failure status at admission between remdesivir and control groups. Subgroup analyses identified specific patient populations that may benefit most from remdesivir treatment, considering factors such as respiratory status and renal function.
resultsThe overlap weighting (OW)-adjusted odds ratio (OR) for mortality in overall cohort, mild cases without supplemental oxygen, moderate cases requiring supplemental oxygen, and severe cases requiring ventilation was (OR, 0.65 (95% confidence interval (CI), 0.36-1.19; P = 0.16), 0.11 (95% CI, 0.01-1.03; P = 0.05). 0.82 (95% CI, 0.31-2.16; P = 0.69), and 0.78 (95% CI, 0.28-2.17; P = 0.63), respectively. A trend toward improvement in mortality was observed in respiratory indicators, such as SpO2 ≥ 94% (OR, 0.43; 95% CI, 0.19-0.99; P = 0.04), oxygen support with FiO2 < 0.5 (OR, 0.40; 95% CI, 0.16-0.97; P = 0.04), and PFR ≥ 300 (OR, 0.17; 95% CI, 0.03-0.94; P = 0.04). Subgroup analyses indicated improved mortality in patients with an estimated glomerular filtration rate (eGFR) of > 60 mL/min per 1.73 m
conclusionRemdesivir treatment may reduce the risk of in-hospital mortality in patients with mild respiratory distress. Subgroup analysis suggested that remdesivir treatment may improve mortality in patients with eGFR ≥ 60 mL/min per 1.73 m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.